
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated strong financial performance, with glaucoma revenue reaching $110 million in Q3 2025, surpassing consensus estimates of $101 million and reflecting a 45% growth compared to the previous quarter. The company's domestic glaucoma revenue also exceeded expectations at $81 million, achieving a 57% increase, while overall international glaucoma revenue grew 17% year-over-year. Furthermore, Glaukos has revised its revenue expectations for the iDose product to approximately $136.8 million for FY25, indicating positive momentum and increasing investor confidence in its innovative product lineup.
Bears say
Glaukos Corp faces a negative financial outlook primarily due to anticipated lower growth in the minimally invasive glaucoma surgery (MIGS) market, along with a slower-than-expected uptake of its iDose and infinite surgical devices. The company's legacy surgical glaucoma revenue has already declined by 4.7% to $40.8 million, and projections indicate a potential material decline in Corneal Health revenues tied to the transition of Epioxa. Additionally, external factors such as changes in the reimbursement landscape and increased competition from new market entrants further exacerbate the company's financial challenges.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares